EFFECT OF OXIRACETAM COMBINED WITH XUESHUANTONG INJECTION ON SERUM HMGB1, PLGF, Β2-MG AND CYST-C IN PATIENTS WITH CEREBRAL INFARCTION

Yanping Ma^{1, *}, Xiaofeng Zhang², Fenlin Li¹, Yanyan Han³, Yuanming Lu⁴, Qiaoli Song⁵

¹Department of Geriatrics, People's Hospital, Chengyang District, Qingdao, PR China - ²Department of Gynecology, People's Hospital of Chengyang District, Qingdao, PR China - ³Department of Obstetrics, People's Hospital, Chengyang District, Qingdao, PR China - ⁴Department of Neurology, The First People's Hospital of Guangyuan, Guangyuan, PR China - ⁵School of Nursing, Zhangjiakou University, Zhangjiakou, PR China

Objective: The objective is to study the effect of oxiracetam combined with the Xueshuantong injection on the high mobility group protein B1 (HMGB1), placental growth factor (PLGF), β2-microglobulin (β2-MG), and cystatin C (Cyst-C) serum in patients with cerebral infarction.

Methods: From June 2017 to January 2019, 108 patients with cerebral infarction were treated in the Department of Neurology in our hospital and were randomly divided into a study group (n = 54) and control group (n = 54) according to the random number table method. Both groups of patients were given diet control, exercise therapy, and health education during treatment. The patients in the control group were treated with oxiracetam, and the patients in the study group were treated with oxiracetam combined with the Xueshuantong injection. Both groups of patients were treated continuously for 7 weeks. The patients were evaluated according to the evaluation standard of the curative effect of cerebral infarction. The National Institutes of Health Stroke Scale (NIHSS) and Mental State Examination Scale (MMSE) scores were used to evaluate the neurological function of the patients. The levels of HMGB1, PLGF, β2-MG, and Cyst-C were measured via enzyme-linked immunosorbent assay (ELISA) before and after treatment. The level of malondialdehyde (MDA) was determined via the thiobarbituric acid method. The activity of glutathione peroxidase (GSH-Px) was detected using the colourimetric method. The activity of superoxide dismutase (SOD) was detected using the enzyme rate method. The level of oxidised low-density lipoprotein (ox LDL) was measured using an ELISA.

Results: After treatment, the total effective rates of clinical treatment were 94.44% in the study group and 79.63% in the control group. The rate was significantly higher in the study group than in the control group (P<0.05). After treatment, the MMSE scores of the two groups of patients were significantly higher than those before treatment, and the NIHSS scores were markedly lower than those before treatment. The MMSE score of the study group was obviously higher than that of the control group, and the NIHSS score of the study group was remarkably lower than that of the control group (P<0.01). After treatment, the levels of HMGB1, PLGF, β2-MG, and Cyst-C in both groups of patients were significantly lower than those before treatment, and the indices of patients in the study group decreased more obviously (P<0.05). After treatment, the levels of SOD and GSH-Px in both groups of patients were significantly higher than those before treatment, whereas the levels of MDA and ox LDL were remarkably lower than those before treatment. The SOD and GSH-Px levels in the study group were obviously higher than those in the control group, whereas the MDA and ox LDL levels in the study group were markedly lower than those in the control group (P<0.05).

Conclusion: The combination of oxiracetam and Xueshuantong in the treatment of patients with cerebral infarction can significantly reduce the levels of HMGB1, PLGF, β2-MG, and Cyst C, alleviate the degree of oxidative stress injury, and improve the neurological function of patients. Moreover, the clinical effect is obvious.